4-[6-[3-(anilinomethyl)phenyl]-8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide
C33H34N6O — CID 123258800
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[6-[3-(anilinomethyl)phenyl]-8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide
4-[6-[3-(anilinomethyl)phenyl]-8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide (PubChem CID 123258800) has the molecular formula C33H34N6O and a molecular weight of 530.68 g/mol. Its IUPAC name is 4-[6-[3-(anilinomethyl)phenyl]-8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide.
Molecular Properties
| Compound Name | 4-[6-[3-(anilinomethyl)phenyl]-8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide |
|---|---|
| PubChem CID | 123258800 |
| Molecular Formula | C33H34N6O |
| Molecular Weight | 530.68 g/mol |
| Exact Mass | 530.28 |
| IUPAC Name | 4-[6-[3-(anilinomethyl)phenyl]-8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide |
| SMILES | CC(C)CNc1nc(-c2cccc(CNc3ccccc3)c2)cn2c(-c3ccc(C(=O)NC4CC4)cc3)cnc12 |
| InChI | InChI=1S/C33H34N6O/c1-22(2)18-35-31-32-36-20-30(24-11-13-25(14-12-24)33(40)37-28-15-16-28)39(32)21-29(38-31)26-8-6-7-23(17-26)19-34-27-9-4-3-5-10-27/h3-14,17,20-22,28,34H,15-16,18-19H2,1-2H3,(H,35,38)(H,37,40) |
| InChIKey | QFBVSXSLTORDMA-UHFFFAOYSA-N |
| XLogP | 6.64 |
| TPSA | 83.35 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 530.68 |
| LogP ≤ 5 | 6.64 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 123258800 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.